# Potential therapeutic effects of ibudilast and retinoic acid against cuprizone-induced behavioral and biochemical changes in mouse brain

**Authors:** Kholoud A. Alyami, Gadah A. Alshahrany, Kholoud M. Al-Otaibi, Mohammad Z. Alam, Badrah S. Alghamdi, Hadeil M. Alsufiani, Nouf O. Alshareef, Hanna M. Alhoraibi, Sahar A. Alkhodair, Ulfat M. Omar

PMC · DOI: 10.3389/fnmol.2025.1567226 · Frontiers in Molecular Neuroscience · 2025-05-20

## TL;DR

This study shows that retinoic acid and ibudilast can help reduce MS-like symptoms in mice by improving motor and cognitive functions and reducing harmful gene activity.

## Contribution

The study demonstrates the combined therapeutic potential of retinoic acid and ibudilast in mitigating MS-related effects in a mouse model.

## Key findings

- Retinoic acid and ibudilast improved locomotor activity, coordination, and cognitive functions in MS-like mice.
- The treatments reduced the expression of harmful genes like TNF-α and COX-2 in the mouse brain.
- Combining retinoic acid with ibudilast showed enhanced therapeutic effects compared to individual treatments.

## Abstract

Ibudilast (IBD) is a new drug that has been released as treatment for multiple sclerosis (MS). Retinoic acid (RA), a metabolite of vitamin A, is known for its pro-regenerative and anti-inflammatory properties, therefore, it has been suggested as a supplementary treatment for MS. The objective of this study is to investigate the therapeutic effects of RA and IBD against cuprizone (CPZ) induced mouse models. Seventy-two Swiss Albino male Mice (SWR/J) were divided into two main groups control (n = 18); normal chow and CPZ (n = 54); 0.25% of CPZ mixed into chow at demyelination stage (first 5 weeks). The following 4 weeks included two stages of remyelination: early remyelination (2 weeks after CPZ discontinuation) and late remyelination (week 9). In the early stage of remyelination, the CPZ group was divided into four subgroups beside daily treatment intraperitoneal injections CPZ (+ve control- no treatment), RA (20 mg/kg), IBD (10 mg/kg), and RA + IBD, with (n = 12/group), while the control group had 12 mice. At the end of each stage 6 mice/ group were sacrificed. Mice response to different treatments was assessed using several locomotor and cognitive behavior tests including open field test, rotarod test, grip strength test, novel object recognition test (NORT) and Y-maze test. The expression levels of several genes MS associated genes Tumer Necrosis Factor- Alpha (TNF- α), Cyclooxygenase-2 (COX-2), Nerve Growth Factor (NGF), Signal transducer and activator of transcription 3 (STAT-3) and Nuclear factor kappa-light-chain-enhancer of activated b-cell (NFKB-P105) in the brain of mice were measured using quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR) analysis. The results demonstrated that RA supplementation helped in alleviating the symptoms of MS induced mice with or without using IBD treatment. This was indicated as an improvement in locomotor activity, motor coordination and muscular strength as well as improving the cognition and memory functions. The mRNA expression pattern of various MS associated genes indicated that the treatments effectively mitigated the detrimental effects of CPZ in mouse brain. The findings of this study indicate that RA supplements could be effectively unitized as adjuvant therapy alongside with IBD for MS treatment.

## Linked entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124], COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513], NGF (nerve growth factor) [NCBI Gene 4803], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Chemicals:** ibudilast (PubChem CID 3671), retinoic acid (PubChem CID 444795), cuprizone (PubChem CID 9723)
- **Diseases:** multiple sclerosis (MONDO:0005301)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Ptgs2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 19225] {aka COX2, Cox-2, PES-2, PGHS-2, PHS II, PHS-2}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, Ngf (nerve growth factor) [NCBI Gene 18049] {aka Ngfb, beta-NGF}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}
- **Diseases:** inflammatory (MESH:D007249), MS (MESH:D009103)
- **Chemicals:** CPZ (MESH:D003471), RA (MESH:D014212), vitamin A (MESH:D014801), IBD (MESH:C038366)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12129909/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12129909/full.md

## References

99 references — full list in the complete paper: https://tomesphere.com/paper/PMC12129909/full.md

---
Source: https://tomesphere.com/paper/PMC12129909